Renaissance Technologies
CGON icon

Renaissance Technologies’s CG Oncology CGON Stock Holding History

Renaissance Technologies’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-46,100
Closed -$1.2M – 3545
2025
Q2 		$1.2M Buy
+46,100
New +$1.11M ﹤0.01% 2408
2024
Q3 		– Sell
-43,200
Closed -$1.36M – 3560
2024
Q2 		$1.36M Buy
43,200
+29,000
+204% +$1.01M ﹤0.01% 2133
2024
Q1 		$623K Buy
+14,200
New +$580K ﹤0.01% 2773

Other funds holding CGON

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies's CGON Position: Q3 2025 in Review

Renaissance Technologies sold out of CG Oncology (CGON) in Q3 2025, closing a stake of 46,100 shares — an estimated $1.2M sold.

Renaissance Technologies first reported a position in CGON in Q1 2024 and held it in 3 quarters. The position peaked at $1.36M in Q2 2024. 176 funds tracked by Wall St. Rank hold CGON as of Q3 2025.

  • Renaissance Technologies reported no remaining CG Oncology position as of Q3 2025 after selling out during the quarter.
  • Renaissance Technologies sold 46,100 CG Oncology shares in Q3 2025, an estimated $1.2M.
  • Renaissance Technologies first reported a position in CG Oncology in Q1 2024 and held it in 3 quarters.
  • Renaissance Technologies's CG Oncology position peaked at $1.36M in Q2 2024.
  • 176 funds tracked by Wall St. Rank held CG Oncology as of Q3 2025.

Based on Renaissance Technologies's 13F filing for Q3 2025, filed 13 Nov 2025.